Tapinarof cream for the treatment of atopic dermatitis: Efficacy and safety results from two Japanese phase 3 trials
The Journal of Dermatology · 2024
DOI: 10.1111/1346-8138.17451 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift The Journal of Dermatology, 2024. Verfasst von Atsuyuki Igarashi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Igarashi Dermatology Higashigotanda, Tokyo, Japan. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Skin Cream. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Tapinarof is a nonsteroidal, topical, aryl hydrocarbon receptor agonist. We evaluated the efficacy and safety of tapinarof cream 1% in Japanese patients aged ≥12 years with atopic dermatitis (AD) in two phase 3 trials, ZBB4‐1 and ZBB4‐2. ZBB4‐1 ( N = 216) consisted of an 8‐week, double‐blind, vehicle‐controlled treatment period (period 1) and a 16‐week extension treatment period (period 2). Patients were randomized 2:1 to tapinarof or vehicle in period 1; subsequently, all patients who enrolled in period 2 received tapinarof. ZBB4‐2 ( N = 291) was a 52‐week, open‐label, uncontrolled trial in which all patients received tapinarof. In period 1 of ZBB4‐1, the proportion of patients who achieved an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) with ≥2‐grade improvement from baseline at week 8 (IGA treatment success, the primary end point) was 20.24% in the tapinarof group and 2.24% in the vehicle group ( p = 0.0007). The proportion of patients with ≥75% improvement from baseline in Eczema Area and Severity Index (EASI) score at week 8 (EASI‐75 response, the key secondary end point) was 40.3% in the tapinarof group and 4.3% in the vehicle group ( p < 0.0001). In ZBB4‐2, IGA treatment success rate was 28.1% at week 16, 32.3% at week 24, and 41.3% at week 52, and EASI‐75 response rate was 53.3% at week 16, 63.7% at week 24, and 76.6% at week 52, indicating that efficacy responses improved over time and were maintained over 52 weeks. Across the two trials, most adverse events (AEs) were mild or moderate; common AEs included folliculitis, acne, and headache. In summary, tapinarof cream 1% was effective and generally safe for up to 52 weeks of treatment in Japanese patients with AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Igarashi Dermatology Higashigotanda, Tokyo, Japan.
- Research and Clinical Center for Yusho and Dioxin, Kyushu University, Fukuoka, Japan.
- Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
- Japan Tobacco Inc., Tokyo, Japan.
ORCID-Profile: Shuichi Fukasawa
Zitieren
APA
Igarashi, A., Tsuji, G., Fukasawa, S., Murata, R., & Yamane, S. (2024). Tapinarof cream for the treatment of atopic dermatitis: Efficacy and safety results from two Japanese phase 3 trials. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17451
Vancouver
Igarashi A, Tsuji G, Fukasawa S, Murata R, Yamane S. Tapinarof cream for the treatment of atopic dermatitis: Efficacy and safety results from two Japanese phase 3 trials. The Journal of Dermatology. 2024. doi:10.1111/1346-8138.17451
BibTeX
@article{Igarashi2024,
author = {Igarashi, Atsuyuki and Tsuji, Gaku and Fukasawa, Shuichi and Murata, Ryusei and Yamane, Satoshi},
title = {Tapinarof cream for the treatment of atopic dermatitis: Efficacy and safety results from two Japanese phase 3 trials},
journal = {The Journal of Dermatology},
year = {2024},
doi = {10.1111/1346-8138.17451}
}
EUVIMED